透析患者の脂質代謝異常　第３９回　日本透析医学会教育講演より

• 西沢 良記

  大阪市立大学第2内科

書誌事項

タイトル別名

• Hyperlipoproteinemia in patients on hemodialysis and CAPD.

抄録

Patients on hemodialysis are at an increased risk for atherosclerosis, and metabolic abnormalities associated with uremia may stimulate the atherosclerosis. Major lipid abnormalities in hemodialysed and CAPD patients are hypertriglyceridemia, hypercholesterolemia, lower level of HDL-cholesteroleremia and higher level of IDL. CAPD patients with hyperlipoproteinemia had significantly higher serum albumin level, and which correlated with apo B level as same as the pathophysiology of nephrotic syndrome. The mechanisms and pathophysiology of uremic hyperlipotroteinemia were evaluated here, and the effectiveness and safety of clinofibrate and pravastatin were shown in the patients on hemodialysis and CAPD as a major drug therapy for them. Since serum level of cholesterol correlated positively to the levels of apo B/A-I ratio, non-HDL cholesterol and IDL, cholesterol level was a useful monitoring parameter for the treatment. Our results suggested that the range for drug therapy in hemodialysed patients is over 200mg/dl of serum cholesterol, and the range of goal is less than 180mg/dl.

収録刊行物

• 日本透析医学会雑誌

  日本透析医学会雑誌 28 (4), 313-324, 1995

  一般社団法人 日本透析医学会

キーワード

• 脂質代謝異常
• 高トリグリセライド血症
• 高コレステロール血症
• 低HDLコレステロール血症

詳細情報

• CRID: 1390001204675154560
• NII論文ID: 130003874686
• DOI: 10.4009/jsdt.28.313
• ISSN: 1883082X
• ISSN: 13403451
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可